TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ribomic, Inc. ( (JP:4591) ) has issued an update.
RIBOMIC, Inc. has announced promising results from a Phase 2 clinical trial of their drug umedaptanib pegol, designed to treat achondroplasia in pediatric patients. The trial showed that two patients experienced a significant increase in height growth velocity, with sustained efficacy over two years, potentially positioning RIBOMIC as a key player in developing treatments for this rare disease.
More about Ribomic, Inc.
RIBOMIC is a clinical-stage biopharmaceutical company focusing on the discovery and development of aptamer therapeutics, which are a type of nucleic acid medicine. The company utilizes its RiboART system to discover aptamer drugs aimed at addressing unmet medical needs, including eye diseases and rare childhood diseases such as short stature.
Average Trading Volume: 1,658,255
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen4.28B
See more data about 4591 stock on TipRanks’ Stock Analysis page.